SCHEMBL904733

SCHEMBL904733

COC(=O)c1ccc(S(=O)(=O)NCc2ccc3c(cnn3C)c2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1C Q14123 2/20 0.43
POLB P06746 3/20 0.42
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
HTR2A P28223 1/20 0.41
PASK Q96RG2 1/20 0.41
CDK19 Q9BWU1 1/20 0.41
ALDH1A1 P00352 5/20 0.41
THRB P10828 5/20 0.41
RECQL P46063 4/20 0.41
VNN1 O95497 1/20 0.41
MEN1 O00255 4/20 0.40
MAPT P10636 4/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 1/20 0.40
S100A4 P26447 1/20 0.40
CACNA1H O95180 3/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
NOTUM Q6P988 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL904717 0.89 MAOA (0.43) PDE1CPOLBCCNCCDK8HTR2A
SCHEMBL904760 0.89 POLB (0.41) PDE1CPOLBCCNCCDK8HTR2A
SCHEMBL904721 0.87 POLB (0.40) POLBALDH1A1THRBRECQLMEN1
SCHEMBL904759 0.86 POLB (0.55) PDE1CPOLBCCNCCDK8HTR2A
SCHEMBL904772 0.84 CHRNA7 (0.50) POLBALDH1A1THRBRECQLMEN1
SCHEMBL904735 0.83 CA1 (0.46) POLBALDH1A1THRBRECQLMEN1
SCHEMBL904795 0.79 POLB (0.59) PDE1CPOLBCCNCCDK8ALDH1A1
SCHEMBL904657 0.77 TRPM8 (0.46) PDE1C
SCHEMBL1144917 0.77 PDE1C (0.57) PDE1CCCNCCDK8HTR2APASK
SCHEMBL30041675 0.77 PDE1C (0.57) PDE1CCCNCCDK8HTR2APASK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM6, TRPM5 PDE1C 871/4885POLB 4408/4885CCNC 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.